MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q3
hinzugefügt 12.11.2025
Adverum Biotechnologies Kurzfristige Verbindlichkeiten 2011-2025 | ADVM
Kurzfristige Verbindlichkeiten Jährlich Adverum Biotechnologies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.9 M | 20 M | 32.2 M | 21.3 M | 20.9 M | 19.4 M | 10.7 M | 10.7 M | 9.9 M | 6.57 M | 5.47 M | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 32.2 M | 5.47 M | 16.4 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Aptorum Group Limited
APM
|
4.34 M | $ 1.3 | - | $ 7.09 M |  China |
 |
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 5.01 | 6.26 % | $ 831 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
31.6 M | $ 3.26 | 0.31 % | $ 252 M |  USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
6.21 M | $ 1.06 | -6.19 % | $ 293 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.05 M | $ 0.27 | -3.93 % | $ 588 M |  Israel |
 |
Catalyst Biosciences
CBIO
|
20 M | $ 13.88 | -1.53 % | $ 914 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
121 M | $ 24.01 | 1.65 % | $ 2.84 B | USA |
 |
CorMedix
CRMD
|
11.4 M | $ 11.08 | -3.57 % | $ 564 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
87.8 M | $ 57.6 | 1.62 % | $ 4.86 B |  Schweiz |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
BioVie
BIVI
|
2.27 M | $ 1.39 | -4.03 % | $ 2.05 M | USA |
 |
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
72.8 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
54.1 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
174 M | $ 26.23 | 3.8 % | $ 1.27 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
78.6 M | $ 10.87 | 0.65 % | $ 1.41 B | USA |
 |
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
31.1 M | $ 9.57 | 0.05 % | $ 140 M | USA |
 |
Eton Pharmaceuticals
ETON
|
16.2 M | $ 16.36 | -2.07 % | $ 420 M | USA |
 |
Exelixis
EXEL
|
404 M | $ 41.5 | 1.5 % | $ 12 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
66.3 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
29.9 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
|
Foghorn Therapeutics
FHTX
|
67 M | $ 4.48 | 0.82 % | $ 246 M | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
1.68 B | $ 551.02 | -2.35 % | $ 41.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
63.1 M | $ 2.37 | 3.04 % | $ 14.9 M | USA |
 |
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
1.66 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2.21 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
534 M | $ 11.43 | -0.87 % | $ 739 M | USA |
 |
Biogen
BIIB
|
5.53 B | $ 173.99 | -0.06 % | $ 25.3 B | USA |
 |
Abeona Therapeutics
ABEO
|
13.4 M | $ 5.13 | -4.38 % | $ 110 M | USA |